Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON 2 10 versus ORAP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON 2 10 versus ORAP.
ETRAFON 2-10 vs ORAP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON 2-10 is a combination of the phenothiazine antipsychotic perphenazine and the tricyclic antidepressant amitriptyline. Perphenazine blocks dopamine D2 receptors, reducing dopaminergic neurotransmission in the mesolimbic pathway, while amitriptyline inhibits serotonin and norepinephrine reuptake, enhancing monoaminergic signaling.
Orap (pimozide) is a diphenylbutylpiperidine antipsychotic that selectively blocks dopamine D2 receptors in the central nervous system, with weak antagonism at alpha1-adrenergic and H1-histamine receptors. Its anti-dyskinetic effect in Tourette syndrome may also involve blockade of calcium channels.
1-2 tablets (perphenazine 2 mg / amitriptyline 10 mg) orally 3-4 times daily; max 8 tablets/day.
Initial: 2 mg orally twice daily; maintenance: 2-10 mg twice daily. Maximum 20 mg/day.
None Documented
None Documented
Clinical Note
moderateVorapaxar + Tranilast
"Vorapaxar may increase the anticoagulant activities of Tranilast."
Clinical Note
moderateVorapaxar + Resveratrol
"Vorapaxar may increase the anticoagulant activities of Resveratrol."
Clinical Note
moderateVorapaxar + Nimesulide
"Vorapaxar may increase the anticoagulant activities of Nimesulide."
Clinical Note
moderateVorapaxar + Epoprostenol
"Vorapaxar may increase the antiplatelet activities of Epoprostenol."
The terminal elimination half-life is approximately 9-10 hours for perphenazine and 18-24 hours for amitriptyline; amitriptyline's active metabolite nortriptyline has a half-life of 18-44 hours, necessitating once-daily dosing for maintenance.
Terminal elimination half-life is 20–40 hours (mean 27 hours). Steady-state achieved in 4–7 days.
Elimination is primarily renal (50-70% as metabolites, <5% unchanged) and biliary/fecal (30-50% as metabolites).
Primarily hepatic metabolism; approximately 40% excreted in urine as metabolites, 15% in feces as unchanged drug and metabolites.
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic